Nonsteroidal antiinflammatory drugs: past, present and future

Bianca Rocca, Carlo Patrono

Research output: Contribution to journalArticle

65 Citations (Scopus)


Currently available NSAIDs represent a heterogeneous group of therapeutic agents characterized by a variable benefit/risk profile. The development of a new class of selective COX-2 inhibitors, the coxibs, has contributed importantly to clarifying the discrete roles of COX-2 vs. COX-1 inhibition in different aspects of NSAID-related efficacy and safety. Cardiovascular toxicity has emerged as a previously unrecognized, mechanism-based effect of COX-2 inhibitors. Lessons learned from the many facets of the coxib failure story may help guiding the successful development of a new class of safer NSAIDs, targeting mediators unrelated to arachidonic acid metabolism or molecular targets downstream of COX-isozymes.
Original languageEnglish
Pages (from-to)285-289
Number of pages5
JournalPharmacological research : the official journal of the Italian Pharmacological Society
Publication statusPublished - 2009


  • Anti-Inflammatory Agents, Non-Steroidal
  • Cardiovascular Diseases
  • Cyclooxygenase 2 Inhibitors
  • Gastrointestinal Diseases
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Risk Assessment


Dive into the research topics of 'Nonsteroidal antiinflammatory drugs: past, present and future'. Together they form a unique fingerprint.

Cite this